Title: Impact of neuroimaging on treatment response in depression

**Abstract**

Major depressive disorder (MDD) is a heterogeneous condition in which a wide range of etiologies, risk factors and symptom profiles may be associated with a threshold diagnosis. Response rates in drug treatment are variable and often less than 50% due to a trial-and-error prescription of antidepressants. Despite significant advances in neuroscience, no widely accepted biomarker is available to assist diagnostics or treatment choice for individual patients.

Neuroimaging using fMRI is useful to investigate the pathophysiology of MDD and aid in the identiﬁcation of biomarkers of treatment response. Traditional task-based fMRI analysis has used statistical approaches to locate areas of the brain which are activated differently between patients and control subjects. Several fMRI studies on responses to emotional stimuli found an association between greater baseline activity in regions throughout the dorsal-ventral extent of anterior cingulate (ACC) - medical prefrontal cortex (mPFC) and better treatment response to SSRI medications in depression. Another fMRI study reported that greater pretreatment amygdala activity predicted better outcome of cognitive-behavioral therapy (CBT). These studies suggest that measures of activity in ACC, mPFC and amygdala may differ in patients who benefit from psychotherapy compared with SSRIs.

More recently, resting-state fMRI has become increasingly popular to study for understanding brain network dynamics in MDD. The key findings in neural circuits supporting implicit emotion regulation and reward processing indicate either abnormally increased resting connectivity between amygdala and striatum, and ACC and ventromedial PFC, and decreased resting connectivity between subgenual ACC and cortical areas. Subcortical-ACC resting-state connectivity has shown an increase after SSRI treatment. Such abnormal resting-state connectivity between brain regions may be possible predictors of antidepressant response.

However, it is unlikely that a single clinical or biological marker can guide treatment selection, therefore multiple biological measures may be needed to provide more reliable markers to guide treatment. Recently, computational neuroscience techniques using machine learning are also applied for neuroimaging studies. In our laboratory, we found that the combination measurement of Childhood Abuse Trauma Scale (CATS) and the resting-state connectivity between angular and default mode network - executive network may be able to predict the non-responder for SSRI.

In this lecture, the recent neuroimaging studies including our current research on treatment response in depression will be reviewed and discussed.
